The Opioid Use Disorder Market Size was valued at USD 3.7 Billion in 2023 and is expected to reach USD 9.02 Billion by 2032, growing at a CAGR of 10.4% over the forecast period 2024-2032.
Get More Information on Opioid Use Disorder Market - Request Sample Report
The rapid growth of the opioid use disorder (OUD) market is mainly attributed to the catastrophic opioid epidemic as well as increasing efforts by the government to manage the public health crisis of opioid use. As of 2023, the Centers for Disease Control and Prevention (CDC) estimated that roughly 81,083 people died due to an opioid-involved overdose in the United States, demonstrating a significant requirement for effective treatments. The Substance Abuse and Mental Health Services Administration (SAMHSA) reported that in 2022, approximately 3.7% of U.S. adults aged 18 and over needed OUD treatment. Nevertheless, just 25.1% of individuals who want medications for OUD accessibility them, revealing a significant therapy space. This reflects the opportunity for market growth that exists with the ongoing push for improved access to care. The MAT Act, enacted in December 2022, has provided even greater access to evidence-based treatments by allowing all providers with controlled substance certificates to prescribe buprenorphine for OUD2. This change will expose OUD treatment from the stigma as other behavioural healthcare treatments and lead to the broader integration of substance use disorder care into diverse healthcare sectors.
Moreover, the market expansion is likely to include government efforts like the Biden-Harris administration's announcement in August 2023 of more than $450 million to address the overdose epidemic, which will expand prevention, treatment, and recovery services. High-speed adoption of medicinal-assisted remedy (MAT) as a core strategy in the cure of OUD is additionally fueling market growth.
Drivers
The increasing incidence of opioid addiction globally is fueling the demand for effective treatments.
Enhanced government involvement and funding are promoting awareness and preventive programs, contributing to market growth.
Innovations such as buprenorphine patches offer effective treatment modes, propelling market expansion.
The increasing rate of opioid use disorder (OUD) is one of the major determinants to drive the Opioid Use Disorder (OUD) market to grow as it raised the demand for effective treatment. In 2022, more than 108,000 people in the U.S. died of drug-involved overdoses, including both illicit and prescription drugs. The surge in opioid-related fatalities has prompted substantial legal actions against pharmaceutical companies. For instance, Purdue Pharma and the Sackler family reached a $7.4 billion settlement to resolve litigation over their involvement in the opioid crisis. Those settlements underscore the realization that the crisis was extreme and represented a lapse with accountability being paramount.
There is a greater effort to increase treatment availability because the burden of OUD has continued to grow. In the U.S., starting October 2, 2024, updated regulations for methadone will enable stable patients to receive 28-days supply of take-home medications. The change in policy is to support treatment compliance and convenience for patients. This underscores a growing recognition of the severity of the OUD epidemic and the urgent need to increase treatment capacity to meet the growing need for treatment.
Restraints
Adverse effects like vomiting, respiratory complications, and muscle aches from OUD medications may hinder market growth.
The scarcity of certain treatment options can restrict market expansion.
Insufficient knowledge about OUD and its treatments among the public poses a challenge to market growth.
The adverse effects of drug remedies offered for the treatment of opioid use disorder (OUD) hamper the growth of this market. Medications such as methadone, buprenorphine, and naltrexone relieve withdrawal and opioid cravings but may also provide undesirable side effects including nausea, vomiting, respiratory depression, constipation, and muscle aches. Such side effects frequently discourage patients from following their treatment schedules, increasing failure rates and hindering recovery. Moreover, some drugs come with the risk of dependency, which makes them subject to suspicion from both the healthcare provider and the patient. This process requires constant monitoring of health status and frequent changes in medication, which is difficult in unsophisticated healthcare systems. This challenge underscores the necessity for ongoing research and development to create safer, more tolerable therapeutic alternatives that can effectively treat OUD without imposing additional physical or psychological burdens on patients.
By Drug Class
In 2023, the market share of the Buprenorphine segment was the highest, contributing 58% of the revenue share. There are several factors responsible for this wide usage such as efficacy, safety, and availability. As a partial opioid agonist, buprenorphine is effective in reducing cravings and withdrawal symptoms while producing much less risk of respiratory depression compared with full opioid agonists. The implementation of the MAT Act in December 2022 has further bolstered buprenorphine's market position by removing barriers to prescribing. regulatory change led to the availability and use of buprenorphine by an expanded variety of healthcare providers.
SAMHSA data indicate for instance that the number of patients receiving buprenorphine for OUD has been rising steadily, with a particularly steep rise in market share from 2020 into 2022. The drug's market dominance is complemented by its formulation flexibility by being available as sublingual tablets, films, and long-acting injectables, which accommodates heterogeneous patient preferences and treatment requirements. Furthermore, government initiatives promoting the use of medication-assisted treatment have particularly emphasized buprenorphine due to its favourable safety profile and potential for office-based treatment, making it more accessible than methadone, which requires specialized clinics.
By Route of Administration
The Injectable route of administration dominated the market in 2023 with approximately 60% of the global revenue share. Several factors are responsible for the substantial market share, all addressing patient comfort as well as meeting the needs of healthcare providers. Injectable formulations, especially LAIs, have benefits related to treatment continuity and a lower risk of abuse or diversion. According to the National Institute on Drug Abuse (NIDA), long-acting formulations can assist in apprehending issues related to daily dosing, which is of great advantage for patients suffering from adherence. The availability of various extended-release injectable buprenorphine formulations has improved treatment options, bolstering the growth of this segment since FDA approval. As an example, Sublocade, a monthly injectable product for buprenorphine, has become popular after its approval.
Injectable formulations can offer more steady drug levels and may help prevent relapse and improve other aspects of care. Furthermore, clinical administration of injectables is intended to reduce the risk of misuse or diversion by allowing controlled administration, which is a key area of concern for both regulators and healthcare providers.
By Distribution Channel
Hospital pharmacies segment dominated the market with a 46% revenue share in 2023. Several reasons contribute to this dominant market share as hospitals play a prominent role in opioid use disorder (OUD) management. Hospitals are ideally suited to be primary care facilities with quality personnel and trained professionals capable of providing comprehensive care for OUD patients, especially for those with complex cases or comorbidities. The growing realization of OUD as a medical illness needing urgent care ("integrated or health care") has coincided with the expansion of hospital-based OUD treatment programs. This explained the continued hospital pharmacy dominance in part because they supplied unique distribution systems for methadone and extended-release forms of oral medications, which can be particularly challenging to ensure proper handling of these controlled substances. The National Survey on Drug Use and Health (NSDUH) paper shows that hospital emergency departments are more commonly used by individuals with OUD (opioid use disorder) seeking treatment, highlighting an opportunity for hospital pharmacies to have a major role in the distribution of medication. In addition to these benefits, or maybe a result of them, hospitals have the infrastructure to deliver the more intensive services required for OUD treatment, such as counselling, behavioural therapies, and management of co-occurring mental health conditions, which is in line with the integrated treatment approach advised for by federal standards.
North America held the largest share of the opioid use disorder market in 2023, representing about 66% of the overall market. The large share of the region is resulting from the high OUD prevalence, the presence of advanced healthcare infrastructure and a large number of government initiatives for controlling the opioid epidemic. In the United State there were an estimated 81,083 opioid-involved overdose deaths that is according to the Centers for Disease Control and Prevention (CDC), It stresses the potency of the opioid-impact crisis in the US. Market growth is primarily driven by the persistent measures taken by the U.S. government against the epidemic, with an additional about $450 million being allotted in August 2023 to implement wider prevention, treatment, and recovery services. The region's well-established network of healthcare providers and treatment facilities, coupled with robust regulatory frameworks supporting addiction treatment programs, has contributed to its market leadership.
On the other hand, the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The soaring rise in the market is due to the rising awareness about OUD treatments, growing healthcare infrastructure, and government initiatives for the treatment of individuals with substance abuse. As an example, in countries such as China and India, there has been a recent prioritization of the approaches to achieving medication-assisted treatment programs for OUD. According to the National Narcotics Control Commission of China, drug users with registered treatment have been on the rise, suggesting that the market for OUD therapies will likely expand overall in China.
Do You Need any Customization Research on Opioid Use Disorder Market - Enquire Now
Recent developments
In January 2023, The U.S. Food and Drug Administration (FDA) introduced a new buprenorphine treatment option specific to opioid use disorder (OUD), which broadens dosing options and enhances opportunities for individuals with OUD to achieve long-term recovery.
In March 2023, Indivior PLC (UK), announced to acquire of Opiant Pharmaceuticals, Inc. to expand its offering of treatment for opioid addiction and overdose, focusing on strengthening the company's position in the market.
In August 2023, The Biden-Harris administration unveiled more than $450 million in funding to address the overdose and addiction crisis, strengthen prevention, treatment, and recovery services, and reduce illegal drug supply. These efforts range from expanding CDC's Overdose Data to Action (OD2A) grants, to rural access to naloxone and access to behavioral healthcare.
Key Players
Service Providers / Manufacturers
Indivior PLC (Sublocade, Suboxone)
Alkermes plc (Vivitrol, Aristada)
Purdue Pharma L.P. (Hysingla ER, Butrans)
Braeburn Pharmaceuticals (Brixadi, Probuphine)
BioDelivery Sciences International, Inc. (Belbuca, Bunavail)
Titan Pharmaceuticals, Inc. (Probuphine Implant, ProNeura)
Teva Pharmaceutical Industries Ltd. (Buprenorphine, Naloxone Tablets)
Camurus AB (Buvidal, Episil Oral Liquid)
Mallinckrodt Pharmaceuticals (Methadose, Roxicodone)
Orexo AB (Zubsolv, Abstral)
Key Users
Mayo Clinic
Cleveland Clinic
Johns Hopkins Hospital
Kaiser Permanente
Hazelden Betty Ford Foundation
American Addiction Centers
Acadia Healthcare
Universal Health Services (UHS)
Summit Behavioral Healthcare
The Recovery Village
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 3.7 Billion |
| Market Size by 2032 | USD 9.02 Billion |
| CAGR | CAGR of 10.4% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drug Class (Naltrexone, Buprenorphine, Methadone, Others) • By Route Of Administration (Oral Administration, Injectable Administration, Others) • By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Indivior PLC, Alkermes plc, Purdue Pharma L.P., Braeburn Pharmaceuticals, BioDelivery Sciences International, Inc., Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Mallinckrodt Pharmaceuticals, Orexo AB |
| Key Drivers | • The increasing incidence of opioid addiction globally is fueling the demand for effective treatments. • Enhanced government involvement and funding are promoting awareness and preventive programs, contributing to market growth. |
| Restraints | • Adverse effects like vomiting, respiratory complications, and muscle aches from OUD medications may hinder market growth. • The scarcity of certain treatment options can restrict market expansion. |
Ans. Yes, you can customize the report as per your requirement.
Ans. APAC region is growing with the significant growth rate during forecast period of 2024-2032.
Ans
Ans. The CAGR of the Opioid Use Disorder Market is 14.2% During the forecast period of 2024-2032.
Ans. The projected market size for the Opioid Use Disorder Market is USD 9.02 billion by 2032.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Treatment and Medication Volume (2020-2032)
5.3 Healthcare Spending (2023)
5.4 Adoption of Digital Health Solutions (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Opioid Use Disorder Market Segmentation, By Drug Class
7.1 Chapter Overview
7.2 Naltrexone
7.2.1 Naltrexone Market Trends Analysis (2020-2032)
7.2.2 Naltrexone Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Buprenorphine
7.3.1 Buprenorphine Market Trends Analysis (2020-2032)
7.3.2 Buprenorphine Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3 BELBUCA
7.3.3.1 BELBUCA Market Trends Analysis (2020-2032)
7.3.3.2 BELBUCA Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4 Sublocade
7.3.4.1 Sublocade Market Trends Analysis (2020-2032)
7.3.4.2 Sublocade Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5 Suboxone
7.3.5.1 Suboxone Market Trends Analysis (2020-2032)
7.3.5.2 Suboxone Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.6 Zubsolv
7.3.6.1 Zubsolv Market Trends Analysis (2020-2032)
7.3.6.2 Zubsolv Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.7 Others
7.3.7.1 Others Market Trends Analysis (2020-2032)
7.3.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Methadone
7.4.1 Methadone Market Trends Analysis (2020-2032)
7.4.2 Methadone Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Others
7.5.1 Others Market Trends Analysis (2020-2032)
7.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Opioid Use Disorder Market Segmentation, By Route Of Administration
8.1 Chapter Overview
8.2 Oral Administration
8.2.1 Oral Administration Market Trends Analysis (2020-2032)
8.2.2 Oral Administration Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Injectable Administration
8.3.1 Injectable Administration Market Trends Analysis (2020-2032)
8.3.2 Injectable Administration Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Others
8.4.1 Others Market Trends Analysis (2020-2032)
8.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Opioid Use Disorder Market Segmentation, By Distribution Channel
9.1 Chapter Overview
9.2 Hospital Pharmacies
9.2.1 Hospital Pharmacies Market Trends Analysis (2020-2032)
9.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Retail Pharmacies
9.3.1 Retail Pharmacies Market Trends Analysis (2020-2032)
9.3.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Others
9.4.1 Others Market Trends Analysis (2020-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Opioid Use Disorder Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.2.4 North America Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.2.5 North America Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.2.6.2 USA Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.2.6.3 USA Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.2.7.2 Canada Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.2.7.3 Canada Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.2.8.2 Mexico Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.2.8.3 Mexico Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Opioid Use Disorder Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.1.6.2 Poland Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.1.6.3 Poland Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.1.7.2 Romania Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.1.7.3 Romania Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Opioid Use Disorder Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.2.4 Western Europe Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.2.5 Western Europe Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.2.6.2 Germany Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.2.6.3 Germany Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.2.7.2 France Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.2.7.3 France Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.2.8.2 UK Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.2.8.3 UK Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.2.9.2 Italy Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.2.9.3 Italy Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.2.10.2 Spain Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.2.10.3 Spain Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.2.13.2 Austria Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.2.13.3 Austria Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Opioid Use Disorder Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.4.4 Asia Pacific Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.4.5 Asia Pacific Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.4.6.2 China Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.4.6.3 China Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.4.7.2 India Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.4.7.3 India Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.4.8.2 Japan Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.4.8.3 Japan Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.4.9.2 South Korea Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.4.9.3 South Korea Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.4.10.2 Vietnam Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.4.10.3 Vietnam Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.4.11.2 Singapore Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.4.11.3 Singapore Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.4.12.2 Australia Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.4.12.3 Australia Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Opioid Use Disorder Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.5.1.4 Middle East Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.5.1.5 Middle East Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.5.1.6.2 UAE Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.5.1.6.3 UAE Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Opioid Use Disorder Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.5.2.4 Africa Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.5.2.5 Africa Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Opioid Use Disorder Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.6.4 Latin America Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.6.5 Latin America Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.6.6.2 Brazil Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.6.6.3 Brazil Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.6.7.2 Argentina Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.6.7.3 Argentina Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.6.8.2 Colombia Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.6.8.3 Colombia Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Opioid Use Disorder Market Estimates and Forecasts, By Drug Class (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Opioid Use Disorder Market Estimates and Forecasts, By Route Of Administration (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Opioid Use Disorder Market Estimates and Forecasts, By Distribution Channel (2020-2032) (USD Billion)
11. Company Profiles
11.1 Indivior PLC
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Alkermes plc
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Purdue Pharma L.P.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Braeburn Pharmaceuticals
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 BioDelivery Sciences International, Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Titan Pharmaceuticals, Inc.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Teva Pharmaceutical Industries Ltd.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Camurus AB
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Mallinckrodt Pharmaceuticals
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Orexo AB
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Drug Class
Naltrexone
Buprenorphine
BELBUCA
Sublocade
Suboxone
Zubsolv
Others
Methadone
Others
By Route Of Administration
Oral Administration
Injectable Administration
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Tele-intensive Care Unit Market size was valued at USD 3.38 billion in 2023 & is expected to reach USD 11.96 billion by 2032, growing at a CAGR of 15.09% over the forecast period of 2024-2032.
The STD diagnostics Market was valued at USD 10.05 Bn in 2023 and is expected to grow to USD 18.78 Bn by 2032, growing at a CAGR of 7.2% from 2024 to 2032.
The Conversational AI in Healthcare Market Size was valued at USD 10.80 Billion in 2023 and is expected to reach USD 80.50 Billion by 2032 and grow at a CAGR of 25.02%.
The Alopecia Treatment Market Size was valued at USD 8.80 Billion in 2023, and is expected to reach USD 20.70 Billion by 2032, and grow at a CAGR of 10.48%.
The U.S. Healthcare Payer Services Market Size was valued at USD 34.29 Billion in 2023 and is witness to reach USD 65.31 Billion by 2032 and grow at a CAGR of 7.74% over the forecast period 2024-2032.
The Multiplex Assay Market size is projected to reach USD 8.84 billion by 2032 and was valued at USD 3.05 billion in 2023, with a CAGR growing CAGR of 11.24% during 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
